Distinguished in IgG4-Related Disease

Lingli X. Dong

No. 1095 Jiefang Road, 
Wuhan, CN 
Distinguished in IgG4-Related Disease
No. 1095 Jiefang Road, 
Wuhan, CN 
OverviewLocationsClinical Research

Overview

Lingli Dong practices in Wuhan, China. Dong is rated as a Distinguished expert by MediFind in the treatment of IgG4-Related Disease. Their top areas of expertise are IgG4-Related Disease, Dry Mouth, Sjogren Syndrome, and Dry Eye Syndrome.

Their clinical research consists of co-authoring 125 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 24 articles in the study of IgG4-Related Disease.

Locations

No. 1095 Jiefang Road, Wuhan, 430030, China
Other Locations
Jiefang Avenue 1095, Wuhan, 430030, China
No. 1095 Jiefang Avenue, Wuhan, 430030, China
1095th Jiefang Avenue, Wuhan, 430000, China
Union Hospital, Wuhan, 430022, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
Enrollment Status: Terminated
Publish Date: November 30, 2023
Intervention Type: Drug, Biological
Study Drugs: Otilimab, Tofacitinib, csDMARDs
Study Phase: Phase 3

125 Total Publications

Serum N-Glycan Signatures as Potential Biomarkers for the Detection and Monitoring of IgG4-Related Disease.
Serum N-Glycan Signatures as Potential Biomarkers for the Detection and Monitoring of IgG4-Related Disease.
Journal: Journal of proteome research
Published: July 31, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dong's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 37 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile